PubMed:22270369 / 300-460 JSONTXT

{"project":"sentences","denotations":[{"id":"T3","span":{"begin":0,"end":160},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Aberrant glycosylation of α-DG disrupts its interaction with ligands and causes a certain type of muscular dystrophy commonly referred to as dystroglycanopathy."}

{"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":26,"end":30},"obj":"gene:1605"},{"id":"T1","span":{"begin":98,"end":116},"obj":"disease:C0026850"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Aberrant glycosylation of α-DG disrupts its interaction with ligands and causes a certain type of muscular dystrophy commonly referred to as dystroglycanopathy."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":98,"end":116},"obj":"HP_0003560"}],"text":"Aberrant glycosylation of α-DG disrupts its interaction with ligands and causes a certain type of muscular dystrophy commonly referred to as dystroglycanopathy."}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"22270369-2#26#30#gene1605","span":{"begin":26,"end":30},"obj":"gene1605"},{"id":"22270369-2#98#116#diseaseC0026850","span":{"begin":98,"end":116},"obj":"diseaseC0026850"}],"relations":[{"id":"26#30#gene160598#116#diseaseC0026850","pred":"associated_with","subj":"22270369-2#26#30#gene1605","obj":"22270369-2#98#116#diseaseC0026850"}],"text":"Aberrant glycosylation of α-DG disrupts its interaction with ligands and causes a certain type of muscular dystrophy commonly referred to as dystroglycanopathy."}

{"project":"mondo_disease","denotations":[{"id":"T2","span":{"begin":98,"end":116},"obj":"Disease"},{"id":"T3","span":{"begin":141,"end":159},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0020121"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0018282"}],"text":"Aberrant glycosylation of α-DG disrupts its interaction with ligands and causes a certain type of muscular dystrophy commonly referred to as dystroglycanopathy."}

{"project":"HP-phenotype","denotations":[{"id":"T1","span":{"begin":98,"end":116},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"HP:0003560"}],"namespaces":[{"prefix":"HP","uri":"http://purl.obolibrary.org/obo/HP_"}],"text":"Aberrant glycosylation of α-DG disrupts its interaction with ligands and causes a certain type of muscular dystrophy commonly referred to as dystroglycanopathy."}

{"project":"GlyCosmos15-HP","denotations":[{"id":"T1","span":{"begin":98,"end":116},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"HP:0003560"}],"text":"Aberrant glycosylation of α-DG disrupts its interaction with ligands and causes a certain type of muscular dystrophy commonly referred to as dystroglycanopathy."}

{"project":"GlyCosmos15-MONDO","denotations":[{"id":"T2","span":{"begin":98,"end":116},"obj":"Disease"},{"id":"T3","span":{"begin":141,"end":159},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0020121"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0018282"}],"text":"Aberrant glycosylation of α-DG disrupts its interaction with ligands and causes a certain type of muscular dystrophy commonly referred to as dystroglycanopathy."}

{"project":"sentences","denotations":[{"id":"T3","span":{"begin":0,"end":160},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Aberrant glycosylation of α-DG disrupts its interaction with ligands and causes a certain type of muscular dystrophy commonly referred to as dystroglycanopathy."}

{"project":"GlyCosmos15-Sentences","blocks":[{"id":"T3","span":{"begin":0,"end":160},"obj":"Sentence"}],"text":"Aberrant glycosylation of α-DG disrupts its interaction with ligands and causes a certain type of muscular dystrophy commonly referred to as dystroglycanopathy."}